ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0101

Romosozumab After Denosumab Improves Lumbar Spine and Maintains Total Hip Bone Mineral Density in Postmenopausal Women with Low Bone Mass

Michael R McClung1, Michael A Bolognese2, Jacques P Brown3, Jean-Yves Reginster4, Bente Langdahl5, Norma Ruiz-Santiago6, Yifei Shi6, Maria Rojeski6, Jen Timoshanko7, Cesar Libanati7, Helina Kassahun6 and Mary Oates6, 1Oregon Osteoporosis Center, Portland, OR, 2Bethesda Health Research Center, Bethesda, MD, 3Laval University and CHU de Québec (CHUL) Research Centre, Québec City, Canada, 4University of Liège, Liège, Belgium, 5Aarhus University Hospital, Aarhus, Denmark, 6Amgen Inc., Thousand Oaks, CA, 7UCB Pharma, Brussels, Belgium

Meeting: ACR Convergence 2020

Keywords: Bone density, osteoporosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Osteoporosis & Metabolic Bone Disease Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Romosozumab, an anti-sclerostin antibody that increases bone formation while decreasing bone resorption, reduces fracture risk within 12 months. Here we evaluate the effects of transitioning from denosumab to romosozumab in treatment-naïve patients.

Methods: This phase 2 trial (NCT00896532) enrolled postmenopausal women with a lumbar spine, total hip, or femoral neck T-score ≤ –2.0 and ≥ –3.5. Patients were randomized to placebo or various doses of romosozumab monthly or every 3 months from baseline to month (M) 24, were rerandomized to 12 months of denosumab 60 mg every 6 months or placebo (M24–36), and then all were to receive romosozumab 210 mg monthly for 12 months (M36–48). Results for the overall population have been previously published (McClung et al, J Bone Miner Res 2018; Kendler et al, Osteoporos Int 2019). Here we present data from a subset of patients who were randomized to placebo for 24 months, denosumab (n = 16) or placebo (n = 12) for 12 months, and then romosozumab for 12 months.

Results: In patients who were randomized to placebo followed by denosumab, romosozumab treatment for 12 months maintained BMD gained during denosumab treatment at the total hip (mean change from end of denosumab treatment, 0.9%) and further increased BMD gains at the lumbar spine (mean change from end of denosumab treatment, 5.3%) (Table). As expected, P1NP and CTX levels decreased with denosumab. Upon transition to romosozumab (M36–48), P1NP levels initially increased and gradually returned to baseline by M48 while CTX gradually increased to baseline levels.

In patients who transitioned to romosozumab after 36 months of placebo, BMD increased at the lumbar spine and total hip (Table). P1NP levels initially increased with romosozumab and gradually returned to baseline by M48 while median CTX level remained below baseline with romosozumab treatment.

Conclusion: BMD response in the placebo to romosozumab group was similar to that observed in other studies. Transitioning to romosozumab after 12 months of denosumab further improves lumbar spine BMD and maintains total hip BMD.

Table


Disclosure: M. McClung, Amgen Inc., 1, 2, Myovant, 1; M. Bolognese, Amgen Inc., 1, 2; J. Brown, Mereo Biopharma, 1, Servier, 1, 2, Amgen Inc., 1, 2, Orimed, 1, Janssen, 1; J. Reginster, None; B. Langdahl, Amgen Inc., 1, 2, 3, Novo Nordisk, 1, UCB, 1, 2, Eli Lilly, 1, Gedeon-Richter, 1, Gilead, 1; N. Ruiz-Santiago, Amgen Inc., 1, 2; Y. Shi, Amgen Inc., 1, 2; M. Rojeski, Amgen Inc., 1, 2; J. Timoshanko, UCB Pharma, 1, 2; C. Libanati, UCB Pharma, 1, 2; H. Kassahun, Amgen Inc., 1, 2; M. Oates, Amgen Inc., 1, 2.

To cite this abstract in AMA style:

McClung M, Bolognese M, Brown J, Reginster J, Langdahl B, Ruiz-Santiago N, Shi Y, Rojeski M, Timoshanko J, Libanati C, Kassahun H, Oates M. Romosozumab After Denosumab Improves Lumbar Spine and Maintains Total Hip Bone Mineral Density in Postmenopausal Women with Low Bone Mass [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/romosozumab-after-denosumab-improves-lumbar-spine-and-maintains-total-hip-bone-mineral-density-in-postmenopausal-women-with-low-bone-mass/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/romosozumab-after-denosumab-improves-lumbar-spine-and-maintains-total-hip-bone-mineral-density-in-postmenopausal-women-with-low-bone-mass/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology